About this trial

This is a randomised, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Participants will receive either pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) or radiotherapy (with or without cisplatin) given after surgery alone.

Patient Profile

Patients with resectable locoregionally advanced Head and Neck Squamous Cell Carcinoma

Where’s this trial being run?

St James’s Hospital and St Luke’s Radiation Oncology Network @ St Luke’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: MK-3475-689
Number: 19-39
Full Title:

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Principal Investigator: Dr Cliona Grant
Type: Industry Sponsored

Merck Sharp & Dohme LLC

Recruitment Started: Global: Dec 2018
Ireland: March 2021
Global Recruitment Target: 704
Ireland Recruitment Target: 5